Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Endo Pharmaceuticals Inc. v. Actavis Laboratories UT, Inc., No. 16-1146 (Fed. Cir. Oct. 14, 2016)

Affirmed
Infringement Invalidity (§ 102/§ 103) Summary Judgment
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 16-1146
Decided
October 14, 2016
Judge
Taranto, J.
Document
Nonprecedential Opinion
Length
13 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Strakan International S.à r.L. owns U.S. Patent Nos. 6,579,865 (issued in 2003) and 6,319,913 (issued in 2001), with priority dating to 1997 . Endo Pharmaceuticals Inc. is the exclusive United States licensee of those patents. In December 2010, Endo obtained final approval from the Food and Drug Administration to market its testosterone gel product, called Fortesta®, which is used by applying it to the skin to deliver testosterone transdermally.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error